GRI Bio, Inc. (GRI )

Currency in USD Disclaimer
$1.32 +$0.74 (127.59%)
Closed 10/21/2024
$1.04
$1.79
$0.3
$134.68

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol GRI
  • Company GRI Bio, Inc.
  • Price $1.32
  • Changes Percentage 127.59
  • Change 0.74
  • Day Low $1.04
  • Day High $1.79
  • Year High $134.68
  • Year Low $0.3
  • Market Cap $3,864,577
  • Price Avg 50 EMA (D) $0.47
  • Price Avg 200 EMA (D) $7.03
  • Exchange NASDAQ
  • Volume 115,820,021
  • Average Volume 1,659,245
  • Open $1.67
  • Previous Close $0.58
  • EPS 57.07
  • PE 0.02
  • Earnings Announcement 2024-11-12 00:00:00
  • Shares Outstanding $2,927,710

Company brief: GRI BIO, INC. (GRI )

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

GRI Corporation News

GRI Bio Announces Exercise of Warrants

GRI Bio Announces Exercise of Warrants

October 21, 2024 at 9:35 pm ET

globenewswire.com -- LA JOLLA, CA, Oct. 21, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cel...

Income Statement